Introduction to CJC-1295
CJC-1295 is a synthetic peptide that functions as a growth hormone-releasing hormone (GHRH) analog. It belongs to a class of research compounds designed to stimulate the body’s natural production of growth hormone (GH). First developed in the early 2000s, CJC-1295 has become one of the most studied GHRH analogs in research settings, with over two decades of scientific investigation supporting its mechanism of action.
Unlike direct growth hormone supplementation, CJC-1295 works by signaling the pituitary gland to increase its natural production of growth hormone. This approach preserves the body’s endocrine feedback loops and produces more physiologically natural GH pulses rather than continuous elevation.
Important Note: CJC-1295 is sold for research purposes only. This article is for educational purposes and does not constitute medical advice. Always consult with a qualified healthcare professional before considering any new compound.
How CJC-1295 Works in Research Models
Mechanism of Action
CJC-1295 operates through a well-understood biological pathway:
- Binds to GHRH Receptors: The peptide attaches to specific receptors in the anterior pituitary gland
- Stimulates GH Secretion: This binding triggers the release of growth hormone in pulsatile patterns
- Increases IGF-1 Levels: Released GH signals the liver to produce insulin-like growth factor-1 (IGF-1)
- Extended Half-Life: When combined with DAC (Drug Affinity Complex), CJC-1295 has a half-life of 6-8 days compared to natural GHRH’s mere minutes
DAC vs. No DAC: Understanding the Difference
CJC-1295 is available in two primary forms:
| Feature | CJC-1295 with DAC | CJC-1295 without DAC |
|---|---|---|
| Half-life | 6-8 days | ~30 minutes |
| GH Pattern | Sustained elevation | Pulsatile bursts |
| Dosing frequency | Less frequent | More frequent |
| Research preference | Sustained release studies | Natural rhythm studies |
The DAC modification binds the peptide to serum albumin in the bloodstream, dramatically extending its active period. Research protocols choose between these forms based on the specific study objectives.
Key Research Findings on CJC-1295
Clinical Study Highlights
A landmark 2006 dose-escalation study (Ionescu & Frohman, PMID: 16682504) demonstrated that CJC-1295 administration in healthy adults produced:
- GH increases of 200-1000% above baseline levels
- IGF-1 elevation of 1.5-3 fold sustained over multiple days
- Dose-dependent response at ranges of 30-120 mcg/kg subcutaneously
- Extended duration of effect lasting 6+ days with the DAC formulation
Primary Areas of Research Interest
1. Muscle Mass and Body Composition
Research indicates CJC-1295 may support:
- Increased lean muscle mass development
- Enhanced metabolic rate and fat oxidation
- Improved protein synthesis
- Satellite cell activation in muscle tissue models
2. Recovery and Repair Mechanisms
Studies have explored CJC-1295’s role in:
- Accelerated injury healing rates
- Tissue repair processes
- Collagen synthesis
- Joint and connective tissue health
3. Sleep and Cognitive Function
Research models suggest potential effects on:
- Deep sleep quality and duration
- Memory consolidation during sleep
- Mental clarity and focus
- Cognitive processing speed
4. Anti-Aging and Longevity Research
Emerging research areas include:
- Skin elasticity and collagen production
- Cellular repair mechanisms
- Immune system modulation
- Neurological protection pathways
CJC-1295 and Ipamorelin: A Research Synergy
CJC-1295 is frequently studied in combination with Ipamorelin, a growth hormone secretagogue. This combination has attracted research interest because:
- Complementary mechanisms: CJC-1295 acts on GHRH receptors while Ipamorelin acts on ghrelin receptors
- Amplified GH response: Combined administration produces greater GH elevation than either compound alone
- Preserved natural pulses: The combination maintains physiologically natural GH pulsatility
- Reduced potential for desensitization: Lower effective doses may reduce receptor downregulation
A recent article on Ipamorelin research provides additional context on how these peptides work together.
Research Protocols and Dosage Considerations
Typical Research Parameters
Research protocols for CJC-1295 typically specify:
With DAC:
- Concentration: Usually 2mg reconstituted in bacteriostatic water
- Research administration: Subcutaneous injection
- Frequency: Typically 1-2 times per week in studies
- Duration: Extended release allows less frequent dosing
Without DAC:
- Often combined with Ipamorelin in research stacks
- Frequency: Multiple administrations per day in research settings
- Rationale: Mimics natural pulsatile GH patterns
Storage and Handling
Proper research compound storage includes:
- Lyophilized powder: Store at -20C in airtight containers
- Reconstituted solution: Store at 2-8C (refrigerated)
- Light protection: Keep away from direct light
- Use within: 30-60 days after reconstitution
Important: Always verify proper handling protocols with your research facility guidelines and refer to the Certificate of Analysis (COA) for specific storage requirements.
Safety Profile and Considerations
Research Safety Observations
Clinical studies have generally reported favorable safety profiles for CJC-1295, including:
- Preservation of endocrine feedback loops
- No significant impact on cortisol, prolactin, or thyroid function
- Generally well-tolerated in controlled settings
- Minimal acute adverse effects in research subjects
Important Considerations for Research
Researchers should be aware of:
- Individual variation: GH response varies significantly between subjects
- Timing factors: Natural GH peaks occur during sleep, affecting study design
- DAC considerations: Continuous stimulation may not suit all research objectives
- Combination effects: Stacking with other peptides requires careful dose adjustment
Contraindications and Warnings
Research should not involve subjects with:
- Active cancer or history of malignancy
- Proliferative eye disorders
- Known hypersensitivity to peptide compounds
- Pregnant or nursing individuals
Frequently Asked Questions About CJC-1295
What is the difference between CJC-1295 and synthetic HGH?
CJC-1295 stimulates the body’s natural production of growth hormone, while synthetic HGH directly introduces exogenous hormone. This fundamental difference means CJC-1295 preserves the pituitary gland’s role and maintains natural pulsatile GH patterns.
How long does CJC-1295 stay active in the body?
The DAC formulation has a half-life of 6-8 days due to albumin binding, providing sustained activity. The non-DAC form has a much shorter half-life of approximately 30 minutes.
Can CJC-1295 be used for anti-aging research?
CJC-1295 has been studied in the context of age-related GH decline. However, all such research is experimental and should be conducted under appropriate oversight with proper protocols.
What is the typical research dose for CJC-1295?
Research studies have used doses ranging from 30-120 mcg/kg subcutaneously. Dose selection depends on the specific research objectives and whether DAC or non-DAC formulations are used.
Is CJC-1295 legal for research purposes?
CJC-1295 is sold as a research compound and is legal to purchase for legitimate research purposes. However, regulations vary by jurisdiction, and researchers should verify local requirements.
How does CJC-1295 compare to other GHRH analogs?
CJC-1295 offers extended duration compared to native GHRH and earlier analogs like Sermorelin. Its DAC modification provides unique sustained-release properties not found in other GHRH peptides.
Compliance and Disclaimer
FOR RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION.
This article is provided for educational and informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
- CJC-1295 is a research compound and is not approved by the FDA for human use
- All research should be conducted in accordance with applicable laws and institutional guidelines
- Proper laboratory safety protocols must be followed when handling research compounds
- Results from research studies may not translate to individual outcomes
- Consult with a qualified healthcare professional before considering any new compound or protocol
BioPharma provides research compounds for legitimate research purposes only. Our products are intended for in vitro testing and laboratory experimentation. We do not condone or support any off-label or unauthorized use of our products.
Conclusion
CJC-1295 represents a significant advancement in growth hormone-releasing peptide research, offering extended action and demonstrated efficacy in stimulating natural GH production. Its mechanism of action – enhancing the body’s own hormonal output rather than introducing exogenous hormone – makes it a valuable tool for researchers studying metabolism, recovery, aging, and body composition.
As with all research compounds, proper handling, storage, and protocol adherence are essential for valid research outcomes. Researchers should always review primary literature, consult COAs for purity verification, and maintain appropriate safety standards.
For more information on related research peptides, explore our guides on BPC-157, TB-500, and the fundamentals of reading a Certificate of Analysis.
Last updated: March 2026